The global transplant diagnostics market size is expected to reach USD 9.74 billion by 2030, registering a CAGR of 7.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. An increasing number of patients suffering from chronic diseases frequently leading to organ failure is creating an upsurge in demand for transplant procedures. In addition, the adoption of stem cell therapy and personalized medicine is escalating, thereby influencing demand for transplant diagnostics.
Risks and complexities associated with organ transplants necessitate the need for improved and sophisticated diagnostic tools. Next-Generation Sequencing (NGS) technology is rapidly replacing traditional diagnostic methods, such as serological techniques employed in Human Leukocyte Antigen (HLA) typing, owing to the growing demand for high-throughput diagnostic tools with enhanced accuracy.
Market growth is expected to be restrained by factors such as reimbursement controversies and ethical issues in some parts of the world. In addition, the high cost of performing HLA matching using Polymerase Chain Reaction (PCR) and NGS devices is challenging the growth of the transplant diagnostics market in developing countries.
Request a free sample copy or view report summary: Transplant Diagnostics Market Report
The sequencing-based typing segment is anticipated to witness significant growth from 2024 to 2030. High adoption of NGS is a major factor driving segment growth
North America captured the largest revenue share in 2023 and is expected to maintain its dominance throughout the forecast period due to well-established research infrastructure, increasing healthcare expenditure, high adoption of advanced diagnostic techniques, and growing R&D activities
Asia Pacific is expected to witness significant growth during the forecast period owing to expanding research opportunities, healthcare expenditure, the medical tourism industry, and awareness regarding organ donation
Grand View Research has segmented the global transplant diagnostics market based on test, product, application, transplant area, end use and region:
Transplant Diagnostics Test Outlook (Revenue, USD Million, 2018 - 2030)
Molecular Assays
PCR-based Molecular Assays
Real-time PCR
Sequence-based Primer-PCR
Sequence-specific Oligonucleotide-PCR
Other PCR-based Molecular Assays
Sequencing-based Molecular Assays
Sanger Sequencing
Next Generation Sequencing
Other Sequencing-based Molecular Assays
Non-molecular Assays
Serological Assays
Mixed Lymphocyte Culture Assays
Transplant Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)
Reagents & Consumables
Instruments
Software and Services
Transplant Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)
Diagnostic Application
Infectious Disease Testing
Histocompatibility Testing
Blood Profiling
Research Application
Transplant Diagnostics Transplant Area Outlook (Revenue, USD Million, 2018 - 2030)
Solid Area Transplantation
Kidney Transplantation
Liver Transplantation
Heart Transplantation
Lung Transplantation
Pancreas Transplantation
Other Organs Transplantation
Stem Cell Transplantation
Soft Tissue Transplantation
Bone Marrow Transplantation
Transplant Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals and Transplant Centers
Research and Academic Institutes
Independent Reference Laboratories
Transplant Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List Of Key Players Transplant Diagnostics Market
Thermo Fisher Scientific, Inc.
Illumina, Inc.
F. Hoffmann La-Roche Ltd
Abbott
QIAGEN
Bruker
BD (Becton, Dickinson and Company)
Werfen (Immucor, Inc.)
Bio-Rad Laboratories, Inc.
Omixon Inc.
"The quality of research they have done for us has been excellent..."